

## TAKE THE FIRST STEP



6:00 PM, WEDNESDAY, 9 JULY 2025 MAKATI SHANGRI-LA HOTEL, MAKATI

Dear Doctor,

We invite you to know more about **Semaglutide 2.4mg (Wegovy)**, a novel holistic option for management for people with obesity providing sustainable double-digit weight loss and cardiovascular benefits beyond weight loss..<sup>1</sup>

## AGENDA

Time	Session	Speaker
6:00	Registration/ Dinner	
7:00	Opening Remarks	Wei Sun General Manager Novo Nordisk Pharmaceuticals (Philippines)
7:10	Session 1: A STEP in the Right Direction in Challenging Visceral Adiposity: New Options to a Difficult Problem	Dr. Angela Gomez, MBA, DPPS, FPAPSHPI Speaker
7:50	Session 2: Going Beyond Obesity: Holistic Approach in Weight Management	Dr. Mark McKelvie, MA (Cantab), MB Bchir, MRCS, PGCME, FHEA <i>Speaker</i>
8:30	Open Forum/ Q&A	Dr. Joseph Andrei Jalipa Bongalo, RN, FPAAAMMI Moderator
8:50	Closing	Ms. Kristanz Nillo Cardiometabolic Sales Director Novo Nordisk Pharmaceuticals (Philippines)

## TAKE THE FIRST STEP TO HEALTHIER BODIES AND BETTER TREATMENT OUTCOMES<sup>1</sup>

Lincoff MA, Brown-Frandsen K, Colhoun H et al. N Engl J Med. 2023;389:2221-32.



PLEASE CLICK/SCAN TO REGISTER



Novo Nordisk Pharmaceuticals (Philippines ) Inc. 21st Fl Twenty-Four Seven McKinley Bldg, 24th Street cor 7th Ave. Bonifacio Global City, Taguig, 1634, Metro Manila, Philippines +63 (02) 8234 3500 nnppisafety@novonordisk.com https://www.novonordisk.ph/ ©2025 Novo Nordisk A/S PH25SEMO00006 June 2025

## FOR HEALTHCARE PROFESSIONALS ONLY

DISCLAIMER: This event is intended for promotion of Novo Nordisk's pharmaceutical products to healthcare professionals. It will contain product related branding and content. You should not forward this invitation without Novo Nordisk's permission.

Full prescribing information available upon request.

You are receiving this message because you previously agreed to receive communications from us.If you wish to unsubscribe to this channel and for data privacy inquiries kindly email privacyph@novonordisk.com

CONFIDENTIALITY NOTICE: The contents of this email are intended solely for the addressee(s) and may contain confidential or privileged information legally protected from disclosure. If you are not the intended recipient of this message, or if this message has been addressed to you in error, please immediately alert the sender by reply email and delete this message and any attachments. If you are not the intended recipient, any use, dissemination, copying or storage of this message or its attachments is strictly prohibited.